Bristol Myers shares rise after positive results from two trials
Bristol Myers Squibb reported positive results from two Phase 3 trials, sending its shares nearly 6% higher in premarket trading on Monday.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Bristol Myers Squibb shares climbed nearly 6% in premarket trading on Monday after the company released positive topline results from two Phase 3 studies, Seeking Alpha reported. The study of admilparant in adults with idiopathic pulmonary fibrosis reached its primary endpoint at the 60 mg dose, with forced vital capacity showing a statistically significant improvement versus placebo at Week 52. The 120 mg dose slowed the decline in forced vital capacity but did not produce a statistically significant result.
A separate Phase 3 study of RYZ101 also met its primary endpoint. Patients with advanced gastroenteropancreatic neuroendocrine tumors whose disease had progressed after lutetium-177-based therapy saw a statistically significant and clinically meaningful improvement in progression-free survival. Safety findings were consistent with the established RYZ101 profile.
why it matters
The results from two late-stage studies could affect how markets assess Bristol Myers Squibb’s pipeline prospects. Seeking Alpha said its content is provided for informational purposes and does not constitute personal investment advice.
instruments
sources
- Bristol Myers jumps as two late-stage trials deliver positive results — Seeking Alpha, 12 October 2026 at 11:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗